Filing Details
- Accession Number:
- 0001209191-15-069921
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-09-09 16:28:57
- Reporting Period:
- 2015-09-04
- Filing Date:
- 2015-09-09
- Accepted Time:
- 2015-09-09 16:28:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp\Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-09-04 | 9,063 | $53.74 | 136,578 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-09-04 | 400 | $124.43 | 136,178 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-09-04 | 5,200 | $125.42 | 130,978 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-09-04 | 3,463 | $126.44 | 127,515 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2015-09-04 | 9,063 | $0.00 | 9,063 | $53.74 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 18,125 | 2022-09-03 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $124.43 (range $123.98 to $124.85).
- Open market sales reported on this line occurred at a weighted average price of $125.42 (range $124.99 to $125.98).
- Open market sales reported on this line occurred at a weighted average price of $126.44 (range $126.00 to $126.92).
- The option vests in 16 quarterly installments from 09/04/2012.
Billionaire Hedge Funds
